Bolt Biotherapeutics, Inc. (BOLT) vs Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

A side-by-side comparison of Bolt Biotherapeutics, Inc. and Cuprina Holdings (Cayman) Limited Class A Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Bolt Biotherapeutics, Inc. logo
BOLT
Bolt Biotherapeutics, Inc.
$7M
$3.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares logo
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$6M
$2.17HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BOLT vs CUPR

growth of $100 · dividends reinvested · last 1y
BOLT -48.4% (-48.4%/yr)CUPR -93.2% (-93.2%/yr)BOLT compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002026$52$7
BOLT CUPR

BOLT vs CUPR: by the numbers

  • •BOLT is the larger company ($7M vs $6M market cap).
  • •Both run net losses; BOLT's is the smaller (-611.47% vs -9366.75% net margin).

Metrics side by side

Valuation

MetricBOLTCUPR
P/S ratio1.44N/A
P/B ratio0.531.48

Profitability

MetricBOLTCUPR
Gross margin80.62%-1.29%
Operating margin-450.07%-9154.62%
Net margin-611.47%-9366.75%
ROE-227.37%-92.44%
ROIC-90.17%-84.15%

Growth (annualized)

MetricBOLTCUPR
Total return CAGR (5Y)-57.61%N/A

Go deeper

Full BOLT analysisFull CUPR analysisInteractive comparison tool

Dig into the metrics

Bolt Biotherapeutics ROECuprina Holdings (Cayman) Limited Class A Ordinary Shares ROEBolt Biotherapeutics operating marginCuprina Holdings (Cayman) Limited Class A Ordinary Shares operating marginBolt Biotherapeutics revenue growthCuprina Holdings (Cayman) Limited Class A Ordinary Shares revenue growthBolt Biotherapeutics free cash flowCuprina Holdings (Cayman) Limited Class A Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.